Impact of different intraocular pressures during cataract surgery on retinal perfusion in eyes with diabetic retinopathy: randomized clinical trial.

J Cataract Refract SurgSep 24, 2026
Clinical ResearchOphthalmology

Shail Vasavada, Shyamal Dwivedi, Vaishali Vasavada et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized clinical trial investigated the effects of low (20 mm Hg) versus high (55 mm Hg) intraocular pressure during cataract surgery on retinal perfusion in patients with nonproliferative diabetic retinopathy. The study found that central retinal vessel density significantly increased in the low IOP group at 1 week and 1 month postoperatively, suggesting improved retinal perfusion.

Key findings

  • Central retinal vessel density significantly increased in the low IOP group at 1 week and 1 month postoperatively.
  • Flux Index improved significantly in the low IOP group at each follow-up visit.
  • Postoperative intraocular pressure was comparable between groups, with a trend toward higher levels in the high IOP group.

Why it matters

Understanding the impact of intraocular pressure during cataract surgery on retinal perfusion is crucial for optimizing surgical outcomes in patients with diabetic retinopathy, potentially reducing the risk of postoperative complications.

Source

PubMed · PMID 41894375

Published in J Cataract Refract Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.